Hans Kristian Moen Vollan
Overview
Explore the profile of Hans Kristian Moen Vollan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
1156
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hoglander E, Nord S, Wedge D, Lingjaerde O, Silwal-Pandit L, Gythfeldt H, et al.
Genome Med
. 2018 Dec;
10(1):92.
PMID: 30497530
Background: Chemotherapeutic agents such as anthracyclines and taxanes are commonly used in the neoadjuvant setting. Bevacizumab is an antibody which binds to vascular endothelial growth factor A (VEGFA) and inhibits...
2.
Dannenfelser R, Nome M, Tahiri A, Ursini-Siegel J, Vollan H, Haakensen V, et al.
Oncotarget
. 2017 Sep;
8(34):57121-57133.
PMID: 28915659
The tumor microenvironment is now widely recognized for its role in tumor progression, treatment response, and clinical outcome. The intratumoral immunological landscape, in particular, has been shown to exert both...
3.
Silwal-Pandit L, Nord S, von der Lippe Gythfeldt H, Moller E, Fleischer T, Rodland E, et al.
Clin Cancer Res
. 2017 May;
23(16):4662-4670.
PMID: 28487444
Chemotherapy-induced alterations to gene expression are due to transcriptional reprogramming of tumor cells or subclonal adaptations to treatment. The effect on whole-transcriptome mRNA expression was investigated in a randomized phase...
4.
Aure M, Vitelli V, Jernstrom S, Kumar S, Krohn M, Due E, et al.
Breast Cancer Res
. 2017 Mar;
19(1):44.
PMID: 28356166
Background: Breast cancer is a heterogeneous disease at the clinical and molecular level. In this study we integrate classifications extracted from five different molecular levels in order to identify integrated...
5.
Silwal-Pandit L, Russnes H, Borgen E, Skarpeteig V, Vollan H, Schlichting E, et al.
PLoS One
. 2015 Oct;
10(10):e0139965.
PMID: 26460974
WRAP53 protein controls intracellular trafficking of DNA repair proteins, the telomerase enzyme, and splicing factors. Functional loss of the protein has been linked to carcinogenesis, premature aging and neurodegeneration. The...
6.
Nielsen H, How-Kit A, Guerin C, Castinetti F, Vollan H, De Micco C, et al.
Endocr Relat Cancer
. 2015 Sep;
22(6):953-67.
PMID: 26400872
Overexpression of insulin growth factor 2 (IGF2) is a hallmark of adrenocortical carcinomas and pheochromocytomas. Previous studies investigating the IGF2/H19 locus have mainly focused on a single molecular level such...
7.
Tinholt M, Vollan H, Sahlberg K, Jernstrom S, Kaveh F, Lingjaerde O, et al.
Breast Cancer Res
. 2015 Apr;
17:44.
PMID: 25882602
Introduction: Hypercoagulability in malignancy increases the risk of thrombosis, but is also involved in cancer progression. Experimental studies suggest that tissue factor (TF) and tissue factor pathway inhibitor (TFPI) are...
8.
Aure M, Jernstrom S, Krohn M, Vollan H, Due E, Rodland E, et al.
Genome Med
. 2015 Apr;
7(1):21.
PMID: 25873999
Background: The role played by microRNAs in the deregulation of protein expression in breast cancer is only partly understood. To gain insight, the combined effect of microRNA and mRNA expression...
9.
Tinholt M, Viken M, Dahm A, Vollan H, Sahlberg K, Garred O, et al.
BMC Cancer
. 2014 Nov;
14:845.
PMID: 25407022
Background: The procoagulant state in cancer increases the thrombotic risk, but also supports tumor progression. To investigate the molecular mechanisms controlling cancer and hemostasis, we conducted a case-control study of...
10.
Quigley D, Silwal-Pandit L, Dannenfelser R, Langerod A, Vollan H, Vaske C, et al.
Mol Cancer Res
. 2014 Oct;
13(3):493-501.
PMID: 25351767
Unlabelled: Lymphocytic infiltration is associated with better prognosis in several epithelial malignancies including breast cancer. The tumor suppressor TP53 is mutated in approximately 30% of breast adenocarcinomas, with varying frequency...